Xeris Biopharma Holdings (XERS) 2025 Conference June 04, 2025 01:25 PM ET Speaker0 Health care conference day one. My name is Dennis Ding. I'm the biotech analyst here at Jefferies. I have the pleasure of having Xeris Biopharma here. We have CEO John Shannon as well as CFO Steve Piper here. Welcome. Speaker1 Thank you. Welcome. Speaker2 Yes, thanks for having us. Speaker0 So maybe to kick things off, just level set us in terms of where you are as a company and maybe talk also about the progress you have mad ...

Xeris Biopharma Holdings (XERS) 2025 Investor Day June 03, 2025 10:00 AM ET Speaker0 Could everyone woah. Take their seats, please. Because we do have people on a live webcast so we want to start on time for them. Okay, two minutes. So everyone, this is your chance to turn your phones off for the ringers. Thank you. I can do it with a whistle, but that's really loud with a mic. Thank you everybody for coming to our very first Analyst and Investor Day. I appreciate you taking the time out of your day and the ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______ to _______ Commission file number: 001-40880 XERIS BIOPHARMA HOLDINGS, INC. (Exact name of the registrant as specified in its charter) Delaware 87-108 ...

Xeris Biopharma Holdings (XERS) Q1 2025 Earnings Call May 08, 2025 08:30 AM ET Company Participants Allison Wey - Senior Vice President of Investor Relations & Corporate CommunicationsJohn Shannon - CEOSteve Pieper - Chief Financial OfficerMazahir Alimohamed - Biotech Equity Research AssociateJason Dorr - Associate Director Conference Call Participants David Amsellem - Sr. Research AnalystChase Knickerbocker - Senior Equity Research Analyst - Healthcare Operator Good morning. Thank you for attending today's ...

Xeris Biopharma Holdings (XERS) Q1 2025 Earnings Call May 08, 2025 08:30 AM ET Speaker0 Good morning. Thank you for attending today's Verisk Biopharma First Quarter twenty twenty five Results Conference Call. My name is Makayah, and I'll be the moderator for today's call. All lines will be muted during the presentation portion of the call with an opportunity for your questions and answers at the end. At this time, I would like to pass the call over to our Senior Vice President of Investor Relations and Corp ...

Xeris Biopharma (XERS) came out with a quarterly loss of $0.06 per share versus the Zacks Consensus Estimate of a loss of $0.07. This compares to loss of $0.14 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 14.29%. A quarter ago, it was expected that this company would post a loss of $0.07 per share when it actually produced a loss of $0.03, delivering a surprise of 57.14%.Over the last four quarters, the company has surpasse ...

Exhibit 99.1 XERIS BIOPHARMA REPORTS RECORD FIRST QUARTER 2025 FINANCIAL RESULTS Total revenue increased 48% YoY to over $60 million Recorlev® revenue grew 141% on YoY basis Tightens full-year total revenue 2025 guidance to $260 million to $275 million Announces upcoming Investor and Analyst Day on June 3 in New York City rd Hosts conference call and webcast today at 8:30 a.m. ET CHICAGO, IL (BUSINESS WIRE); May 8, 2025 – Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical compan ...

Thank you for reading my research on Seeking Alpha. If you want to learn even more about my method and how I discover these investment opportunities, please check out my subscription marketplace service, Compounding Healthcare , and sign up for a free trial.It has been roughly seven months since my last Xeris Biopharma Holdings, Inc. (NASDAQ: XERS ) article , where I pointed out that XERS looked primed to make a big move higher, which forced me to reassessHe is the leader of the investing group Compounding ...

Company Overview - Xeris Biopharma (XERS) shares increased by 5.6% to $5.51 in the last trading session, with a notable trading volume, contributing to a total gain of 34.9% over the past four weeks [1][2] Recent Developments - The FDA approved Xeris' supplemental new drug application for Gvoke VialDx, which is intended to temporarily inhibit gastrointestinal movement during radiologic procedures in adults [2] - Xeris entered a partnership with American Regent to commercialize Gvoke VialDx in the United States, which has likely contributed to the recent optimism and share price increase [2] Financial Expectations - Xeris is projected to report a quarterly loss of $0.07 per share, reflecting a year-over-year improvement of 50% [3] - Expected revenues for the upcoming quarter are $57.75 million, representing a 42.1% increase compared to the same quarter last year [3] Earnings Estimate Revisions - The consensus EPS estimate for Xeris has been revised 10% higher in the last 30 days, indicating a positive trend that typically correlates with stock price appreciation [4] - The stock currently holds a Zacks Rank of 2 (Buy), suggesting favorable market sentiment [4] Industry Context - Xeris Biopharma is part of the Zacks Medical - Drugs industry, where another company, Aurinia Pharmaceuticals (AUPH), saw a 1.7% increase in its last trading session and has returned 3% over the past month [4] - Aurinia's consensus EPS estimate has decreased by 17.5% over the past month, although it reflects a significant year-over-year change of 400% [5]

Financial Performance - Xeris Biopharma Holdings, Inc. reported total revenue of $203.07 million for the year ended December 31, 2024, an increase of 24% compared to $163.91 million in 2023 [521]. - Product revenue, net for 2024 was $196.64 million, up 28% from $153.36 million in 2023 [521]. - The company incurred a net loss of $54.84 million in 2024, compared to a net loss of $62.26 million in 2023, reflecting a 12% improvement [521]. - Total costs and expenses increased to $236.72 million in 2024, up from $207.92 million in 2023, primarily driven by higher selling, general, and administrative expenses [521]. - The company reported a net loss of $54.8 million for the year ended December 31, 2024, compared to a net loss of $62.3 million in 2023 and $94.7 million in 2022, indicating a 12% improvement year-over-year [527]. Cash Flow and Liquidity - Net cash used in operating activities decreased to $37.0 million for the year ended December 31, 2024, from $47.0 million in 2023, primarily due to reduced working capital usage [462]. - Cash and cash equivalents as of December 31, 2024, were $71.62 million, an increase from $67.45 million in 2023 [518]. - The company had cash, cash equivalents, and restricted cash of $75.7 million at the end of 2024, up from $71.7 million in 2023 [529]. - The company expects to continue incurring net losses for at least the next 12 months, but believes current cash resources are sufficient to sustain operations during this period [535]. Debt and Financing - Long-term debt, net of current portion, rose to $217.01 million in 2024, compared to $190.93 million in 2023 [518]. - Total debt increased to $232,108,000 as of December 31, 2024, compared to $190,932,000 in 2023, reflecting a growth of 21.5% [608]. - The Amended and Restated Credit Agreement provided for $200 million in term loans, with an effective interest rate of approximately 11.4% [625]. - The company may finance operations through equity or debt financing, but there is no assurance that such funding will be available on acceptable terms, which could negatively impact financial condition and business strategies [536]. Revenue Recognition and Accounting Policies - The company recognizes revenue when customers obtain control of promised goods, with revenues recorded at the net product sales price after accounting for various allowances [471]. - The company applies significant judgments and estimates in determining allowances for patient copay assistance, commercial rebates, and government rebates, impacting reported revenues [471]. - If the company were to increase or decrease the returns reserve rate by 1%, it would have a $1.8 million impact on revenue for the year ended December 31, 2024 [552]. - The company offers savings programs to commercially insured patients, which are recorded as a reduction of product revenue [546]. Assets and Inventory - The company's total assets slightly increased to $323.06 million in 2024 from $322.60 million in 2023 [518]. - Total inventory as of December 31, 2024, was $48.18 million, compared to $38.84 million in 2023, reflecting a 24% increase [603]. - Inventory reserves increased to $7.7 million at December 31, 2024, from $2.4 million in 2023 [603]. Stock-Based Compensation - Stock-based compensation expenses increased to $18.4 million in 2024 from $10.7 million in 2023, reflecting higher employee incentives [527]. - The total fair value of RSUs vested during 2024 was $10.7 million, compared to $2.8 million in 2023 [656]. - The company recognized total stock-based compensation expense of $18.4 million in 2024, significantly higher than $10.7 million in 2023 [657]. Market Risks - The company is subject to market risks, including interest rate and foreign currency exchange rate fluctuations, but net foreign currency gains and losses did not materially affect operations for the year ended December 31, 2024 [480]. - A hypothetical one-percentage point increase or decrease in interest rates would impact interest income by approximately $0.8 million annually based on cash and investments outstanding as of December 31, 2024 [481]. Internal Controls and Compliance - The company maintained effective internal control over financial reporting as of December 31, 2024, according to the auditor's opinion [505]. - The company adopted several new accounting standards, including ASU 2023-03, with no material impact on financial statements [586].